NASDAQ:NERVMinerva Neurosciences Stock Price, Forecast & News

Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NERV stock has increased by 123.4% and is now trading at $14.21. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Minerva Neurosciences.

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Minerva Neurosciences.

Minerva Neurosciences Inc (NASDAQ:NERV) posted its earnings results on Monday, May, 4th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.05. View Minerva Neurosciences' earnings history.

5 Wall Street analysts have issued twelve-month target prices for Minerva Neurosciences' stock. Their forecasts range from $17.00 to $26.00. On average, they anticipate Minerva Neurosciences' stock price to reach $20.80 in the next year. This suggests a possible upside of 46.4% from the stock's current price. View analysts' price targets for Minerva Neurosciences.

Headlines about NERV stock have trended very negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Minerva Neurosciences earned a news sentiment score of -3.8 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View the latest news aboutMinerva Neurosciences.

Minerva Neurosciences saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 2,820,000 shares, a decrease of 5.4% from the April 30th total of 2,980,000 shares. Based on an average trading volume of 392,500 shares, the short-interest ratio is currently 7.2 days. Approximately 9.0% of the shares of the company are sold short. View Minerva Neurosciences' Current Options Chain.

Some companies that are related to Minerva Neurosciences include Turning Point Therapeutics (TPTX), Ra Pharmaceuticals (RARX), Principia Biopharma (PRNB), TG Therapeutics (TGTX), Karuna Therapeutics (KRTX), Prestige Consumer Healthcare (PBH), SAGE Therapeutics (SAGE), Epizyme (EPZM), IGM Biosciences (IGMS), Pacira Biosciences (PCRX), Ironwood Pharmaceuticals (IRWD), Madrigal Pharmaceuticals (MDGL), Xencor (XNCR), Eidos Therapeutics (EIDX) and Corcept Therapeutics (CORT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include PTC Therapeutics (PTCT), Inovio Pharmaceuticals (INO), Immunomedics (IMMU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), ImmunoGen (IMGN), VBI Vaccines (VBIV), Exelixis (EXEL), TG Therapeutics (TGTX) and Cara Therapeutics (CARA).

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Minerva Neurosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.33%), State Street Corp (1.31%), Geode Capital Management LLC (1.25%), Nuveen Asset Management LLC (1.03%), Acadian Asset Management LLC (0.48%) and Sphera Funds Management LTD. (0.43%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer, Richard E Russell, Venture Associates L Index III and William F Doyle. View institutional ownership trends for Minerva Neurosciences.

NERV stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., JPMorgan Chase & Co., Squarepoint Ops LLC, State Street Corp, GSA Capital Partners LLP, Connor Clark & Lunn Investment Management Ltd., Morgan Stanley, and BlackRock Inc.. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer, and Venture Associates L Index III. View insider buying and selling activity for Minerva Neurosciences.

NERV stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Deutsche Bank AG, Russell Investments Group Ltd., Acadian Asset Management LLC, AQR Capital Management LLC, Geode Capital Management LLC, Two Sigma Advisers LP, and Trexquant Investment LP. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer, and William F Doyle. View insider buying and selling activity for Minerva Neurosciences.

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NERV stock can currently be purchased for approximately $14.21.

Minerva Neurosciences has a market capitalization of $557.32 million. The biopharmaceutical company earns $-72,180,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. Minerva Neurosciences employs 13 workers across the globe.

The official website for Minerva Neurosciences is www.minervaneurosciences.com.

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]